#USA #St. Louis #spray drying #Codis #Particle Engineering

Codis: Pioneering the Future of Pharmaceutical Manufacturing

In an ever-evolving pharmaceutical landscape, Codis emerges as a significant player with its recent launch as a global Contract Development and Manufacturing Organization (CDMO). Combining commercial spray drying capabilities with a deep expertise in particle engineering, Codis aims to set new standards in producing amorphous solid dispersions at a commercial scale.

Formed through the strategic merger of Particle Dynamics and the Haverhill facility previously operated by EUROAPI in the UK, Codis brings together decades of regulatory know-how along with manufacturing excellence, resulting in a robust platform for pharmaceutical innovators.

The new brand operates across a substantial manufacturing footprint of 40,000 square meters in both the US and the UK, giving it one of the largest commercial spray drying operations globally. The combined strengths of Codis's facilities in St. Louis, Missouri, Seymour, Indiana, and Haverhill, UK, allows them to offer more than 5,000 metric tons of spray drying output annually. Currently, they serve around 50 global pharmaceutical clients with a portfolio of 30 products.

Codis is positioned as a reliable partner for pharmaceutical companies that seek to expedite their therapies from the lab to the market. As emphasized by Codis CEO Nicolas Fortin, the company is built on a foundation of quality, compliance, and scale. With three GMP (Good Manufacturing Practice) certified facilities and an extensive track record of successful regulatory approvals from international agencies, Codis is uniquely equipped to meet the needs of its partners. The facility in Haverhill alone is home to over 30 years of expertise in spray drying, continuous flow chemistry, and regulatory compliance. This experience has solidified its reputation as a leading manufacturer of Sevelamer, a crucial product that underscores its capabilities in delivering high-quality pharmaceuticals.

Moreover, Codis stands out as it has garnered approval from six international regulatory agencies, reinforcing its commitment to compliance and quality control. The company's emphasis on problem-solving and adaptability is reflected in its name, which is derived from the Latin term ‘codex,’ representing a systematic approach to business and partnerships.

As Codis leverages its extensive capabilities in commercial spray drying, amorphous solid dispersions, and particle engineering, it is ready to deliver unparalleled service to the pharmaceutical, consumer health, nutraceutical, and over-the-counter (OTC) sectors. The company asserts a proven record of gaining regulatory approvals from major entities including the FDA, EMA, and PMDA, making it a trusted name among leading pharmaceutical companies worldwide.

Through its innovative solutions and industry leadership, Codis is not just a participant in the pharmaceutical manufacturing sector but a pioneer poised to change how drugs are developed and brought to market. With advanced technological capabilities and a dedicated workforce of over 300 employees, Codis ensures that pharmaceutical innovators have the support they need to navigate the complexities of drug manufacturing efficiently.

In conclusion, the emergence of Codis as a global CDMO represents a major advancement in commercial-scale pharmaceutical manufacturing. By integrating cutting-edge technology with years of regulatory expertise, Codis is set to become a go-to partner for pharmaceutical companies worldwide, enabling them to transform their innovative ideas into effective therapies faster than ever before.